{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "exchange": "FRA", "shortName": "VTV THERAPEUTICS A DL-,01", "longName": "vTv Therapeutics Inc.", "messageBoardId": "finmb_304063261", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 0.8, "averageDailyVolume3Month": 50, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 0.4627, "fiftyTwoWeekLowChangePercent": 1.3717759, "fiftyTwoWeekRange": "0.3373 - 1.3205", "fiftyTwoWeekHighChange": -0.5205, "fiftyTwoWeekHighChangePercent": -0.39416888, "fiftyTwoWeekLow": 0.3373, "fiftyTwoWeekHigh": 1.3205, "earningsTimestamp": 1683836100, "earningsTimestampStart": 1683836100, "earningsTimestampEnd": 1683836100, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.26, "epsForward": -0.33, "epsCurrentYear": -0.22, "priceEpsCurrentYear": -3.6363637, "sharesOutstanding": 81483600, "bookValue": -0.132, "fiftyDayAverage": 0.723412, "fiftyDayAverageChange": 0.076588035, "fiftyDayAverageChangePercent": 0.10587057, "twoHundredDayAverage": 0.845599, "twoHundredDayAverageChange": -0.045598984, "twoHundredDayAverageChangePercent": -0.053925067, "marketCap": 65186880, "forwardPE": -2.4242423, "priceToBook": -6.060606, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "regularMarketChangePercent": -3.0303001, "regularMarketPrice": 0.8, "marketState": "REGULAR", "firstTradeDateMilliseconds": 1440396000000, "priceHint": 4, "regularMarketChange": -0.024999976, "regularMarketTime": 1683872571, "regularMarketDayHigh": 0.8, "regularMarketDayRange": "0.8 - 0.8", "regularMarketDayLow": 0.8, "regularMarketVolume": 100, "regularMarketPreviousClose": 0.825, "bid": 0.805, "ask": 0.84, "bidSize": 1200, "askSize": 1200, "symbol": "5VT.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "3980 Premier Drive", "address2": "Suite 310", "city": "High Point", "state": "NC", "zip": "27265", "country": "United States", "phone": "336 841 0300", "fax": "336 841 0310", "website": "https://vtvtherapeutics.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593; and license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.", "fullTimeEmployees": 13, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jonathan L. Isaacsohn FACC, M.D.", "age": 68, "title": "Exec. Chairperson", "yearBorn": 1954, "fiscalYear": 2022, "totalPay": {"raw": 0, "fmt": null, "longFmt": "0"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Paul J. Sekhri M.Sc., MSc", "age": 64, "title": "CEO, Pres & Director", "yearBorn": 1958, "fiscalYear": 2022, "totalPay": {"raw": 483431, "fmt": "483.43k", "longFmt": "483,431"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Steven  Tuch M.B.A.", "age": 53, "title": "Exec. VP & CFO", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 449159, "fmt": "449.16k", "longFmt": "449,159"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Barry  Brown", "age": 61, "title": "Chief Accounting Officer", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": {"raw": 311977, "fmt": "311.98k", "longFmt": "311,977"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Richard S. Nelson", "age": 52, "title": "Exec. VP of Corp. Devel. & Director", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": {"raw": 201081, "fmt": "201.08k", "longFmt": "201,081"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Carmen  Valcarce Ph.D.", "title": "Chief Scientific Officer & Exec. VP", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Vanessa  McDade", "title": "Chief Admin. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Elizabeth M. Keiley", "age": 56, "title": "Exec. VP & Gen. Counsel", "yearBorn": 1966, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}